EUDA Health Holdings Limited

EUDA Health Holdings Limited

EUDA
EUDA Health Holdings LimitedUS flagNASDAQ Capital Market
16.79
USD
+0.06
- -
31.36MMarket Cap
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
19.18
9.85
6.26
3.24
2.47
- -
Basic EPS, GAAP
0.38
1.87
-41.37
-8.77
-9.46
- -
Free Cash Flow per Basic Share
-1.05
0.96
-2.54
-2.55
-1.33
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.76
1.11
-5.64
-6.39
-1.41
- -
Tangible Book Value per Share
-3.87
-1.48
-5.83
-6.53
-1.79
- -
Basic Weighted Avg Shares
- -
- -
1
1
2
- -
Sales/Revenue/Turnover
9
5
4
4
4
7
Operating Margin (%)
-10.07
-12.28
-156.22
-106.87
-64.31
-35.78
Depreciation Expense
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
1
-25
-10
-15
-3
Effective Tax Rate (%)
19.26
2.78
- -
- -
- -
- -
Profit Margin (%)
1.98
18.97
-661.06
-270.86
-382.88
-40.65
Working Capital
-2
-3
-4
-8
-3
-5
LT Debt
- -
- -
- -
- -
- -
- -
Total Equity
- -
1
-4
-7
-3
-4
Return on Invested Capital (%)
- -
-58.91
- -
- -
- -
- -
Return on Capital (%)
- -
113.82
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-171.98%
65.92%
Free Cash Flow
- -
-110.61%
17.68%
Net Income, GAAP
- -
-534.68%
-81.94%
Sales/Revenue/Turnover
- -
2.13%
70.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
2
1
- -
- -
4
2024
- -
- -
- -
- -
4
2025
- -
- -
- -
- -
7

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-2.39
- -
- -
- -
-8.77
2024
- -
- -
- -
- -
-9.46
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Alfred Lim
Full Time Employees
117
Sector
Healthcare
Industry
Medical - Healthcare Information Services
Address
1 Pemimpin Drive Singapore Singapore 576151
IPO Date
Dec 14, 2021
Website
euda.com
Business
EUDA Health Holdings Limited (EUDA) is a Singapore-based health technology company that operates a digital healthcare ecosystem focused on non-invasive, preventive, and holistic wellness solutions primarily in Southeast Asia, including Singapore, Malaysia, and China. The company provides a proprietary AI-powered platform offering e-triage, teleconsultations with general practitioners, digital medical certificates and prescriptions, urgent care services, specialist referrals, mental health support, physiotherapy, health screenings, and medication delivery through its MyEUDA app; lifestyle and wellness products such as bioenergy cabins, Helixe supplements, Yoroyal holistic wellness items via direct selling, e-commerce, and retail channels, wellness therapies, and membership programs; health plans integrating insurers and providers; and property management services for shopping malls, office buildings, residential apartments, and condominiums. Founded in 2019 by Dr. Kelvin Chen and headquartered at 60 Kaki Bukit Place #03-01, Eunos Techpark, Singapore, EUDA targets individual consumers, corporate clients, and employees seeking affordable, accessible care from wellness prevention to post-treatment aftercare. Recent developments include the May 2024 acquisition of CK Health Plus Sdn Bhd for US$15 million in shares to expand direct-selling of holistic wellness products and license bioenergy cabins to spas and salons; a December 2024 announcement of a potential joint venture with Guangdong Cell Biotech for stem cell therapies and regenerative medicine across Asia; and an August 2025 convertible note issuance completed in November 2025 to enhance liquidity amid ongoing strategic growth in the region's US$740 billion healthcare market.

Company News

APIChat
  • EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

  • EUDA Health Expands Helixé Product Line with Launch of Regenixé iPSC-Derived Skin Stem Cell Secretome Mask

  • EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

  • EUDA Health Regains Compliance with Nasdaq Continued Listing Requirements After Receipt of Nasdaq Notification Regarding Minimum Market Value Deficiency

  • EUDA Highlights Shenzhen Inno's Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

  • EUDA Highlights Shenzhen Inno’s Approval Under Shenzhen Key Industry R&D Program for TCR-T Cell Therapy Development

  • EUDA Health Holdings Limited Has Received Notice from Nasdaq that it has Failed to Maintain a Minimum Market Value of its Listed Securities

  • Contrasting EUDA Health (NASDAQ:EUDA) and Outset Medical (NASDAQ:OM)

  • EUDA Announces Reverse Stock Split of its Ordinary Shares

  • EUDA Health Holdings Limited Announces Repurchase and Cancellation of Streeterville Warrant

  • Comparing Hinge Health (NYSE:HNGE) and EUDA Health (NASDAQ:EUDA)

  • EUDA Enters into Convertible Loan Agreement with Shenzhen Inno, Further Expanding Stem Cell Therapy Platform

  • EUDA Health Holdings Limited Announces Amendment to Streeterville Warrant Agreement

  • EUDA Launches Nationwide Stem Cell Extraction, Cryostorage and Clinical Delivery Platform in China with Shenzhen Inno Immune and Wuhan Kaien Hospital

  • EUDA Health to Launch EUDA Helixé 2.0 in January 2026

  • EUDA Accelerates Longevity Strategy with Launch of Comprehensive Stem Cell Therapy Platform and First Clinic in Shenzhen

  • EUDA Health (NASDAQ:EUDA) and Inspire Medical Systems (NYSE:INSP) Head-To-Head Analysis

  • EUDA Integrates QB Utility Token to Create a Digital Health and Rewards Platform Across Its Healthcare Ecosystem

  • EUDA Health Holdings Limited Announces Execution of Securities Purchase Agreement

  • EUDA Signs Letter of Intent to Potentially Acquire GO POSB